Live Breaking News & Updates on Xenon Pharmaceuticals Stock Performance

Stay updated with breaking news from Xenon pharmaceuticals stock performance. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Stock Traders Buy Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)

Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Rating) was the recipient of some unusual options trading on Wednesday. Investors purchased 4,063 put options on the company. This represents an increase of approximately 2,362% compared to the average daily volume of 165 put options. Xenon Pharmaceuticals Stock Performance Shares of XENE opened at $42.03 on Friday. The […] ....

Simon Neil Pimstone , Stifel Nicolaus , Ian Mortimer , Simonn Pimstone , Cubist Systematic Strategies , Xenon Pharmaceuticals Company Profile , Institutional Investors Weigh In On Xenon Pharmaceuticals , Xenon Pharmaceuticals Stock Performance , News Ratings For Xenon Pharmaceuticals Daily , Securities Exchange Commission , Xenon Pharmaceuticals , Needham Company , Royal Bank , Xenon Pharmaceuticals Inc , Wells Fargo Company , Advisors Asset Management Inc , Cantor Fitzgerald , Jpmorgan Chase Co , Insider Activity At Xenon Pharmaceuticals , Get Rating , Exchange Commission , Director Simon , Systematic Strategies , Asset Management , Dark Forest Capital Management , Xenon Pharmaceuticals Daily ,

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Stock Holdings Boosted by Driehaus Capital Management LLC

Driehaus Capital Management LLC grew its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Rating) by 3.9% in the 4th quarter, HoldingsChannel.com reports. The fund owned 4,681,797 shares of the biopharmaceutical company’s stock after acquiring an additional 177,777 shares during the period. Xenon Pharmaceuticals comprises about 2.8% of Driehaus Capital Management LLC’s holdings, […] ....

Ian Mortimer , Simon Neil Pimstone , Simonn Pimstone , Stifel Nicolaus , Driehaus Capital Management , Xenon Pharmaceuticals Profile , Needham Company , Xenon Pharmaceuticals Inc , Xenon Pharmaceuticals , Jpmorgan Chase Co , Marshall Wace , Timessquare Capital Management , Cantor Fitzgerald , News Ratings For Xenon Pharmaceuticals Daily , Securities Exchange Commission , Quarter For Xenon Pharmaceuticals , Xenon Pharmaceuticals Stock Performance , Goldman Sachs Group Inc , Get Rating , Capital Management , Sachs Group , Global Management , Director Simon , Exchange Commission , Visit Holdingschannel , Xenon Pharmaceuticals Daily ,

Xenon Pharmaceuticals (NASDAQ:XENE) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Xenon Pharmaceuticals (NASDAQ:XENE – Get Rating) in a research note released on Thursday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock. A number of other brokerages also recently weighed in on XENE. Needham & Company LLC reissued a buy rating and set a $50.00 target […] ....

United States , Stifel Nicolaus , Simon Neil Pimstone , Simonn Pimstone , Xenon Pharmaceuticals Stock Performance , Xenon Pharmaceuticals , Jpmorgan Chase Co , Institutional Investors Weigh In On Xenon Pharmaceuticals , Geode Capital Management , Analyst Recommendations For Xenon Pharmaceuticals , Cantor Fitzgerald , Xenon Pharmaceuticals Inc , News Ratings For Xenon Pharmaceuticals Daily , Securities Exchange Commission , Royal Bank , Stifel Financial Corp , Needham Company , Get Rating , Moderate Buy , Director Simon , Exchange Commission , State Teachers Retirement System , Financial Corp , State Retirement System , Capital Management , Xenon Pharmaceuticals Daily ,

Xenon Pharmaceuticals (NASDAQ:XENE) Price Target Raised to $53.00

Xenon Pharmaceuticals (NASDAQ:XENE – Get Rating) had its target price boosted by Stifel Nicolaus from $52.00 to $53.00 in a research report released on Wednesday morning, The Fly reports. Several other equities research analysts have also recently issued reports on XENE. StockNews.com initiated coverage on Xenon Pharmaceuticals in a report on Thursday, March 16th. They […] ....

Simonn Pimstone , Simon Neil Pimstone , Stifel Nicolaus , Jpmorgan Chase Co , Marshall Wace , Goldman Sachs Group Inc , Cantor Fitzgerald , Needham Company , Xenon Pharmaceuticals Stock Performance , Analyst Recommendations For Xenon Pharmaceuticals , Royal Bank , News Ratings For Xenon Pharmaceuticals Daily , Xenon Pharmaceuticals Inc , Xenon Pharmaceuticals , Get Rating , Moderate Buy , Director Simon , Sachs Group , Logos Global Management , Xenon Pharmaceuticals Daily , Nasdaq Xene , Boost Price Target ,

Xenon Pharmaceuticals (NASDAQ:XENE) Posts Earnings Results, Misses Estimates By $0.01 EPS

Xenon Pharmaceuticals (NASDAQ:XENE – Get Rating) released its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.01), Briefing.com reports. Xenon Pharmaceuticals had a negative return on equity of 17.90% and a negative net margin of 862.06%. During the same period […] ....

Nova Scotia , Simon Neil Pimstone , Simonn Pimstone , Xenon Pharmaceuticals Stock Performance , Royal Bank , News Ratings For Xenon Pharmaceuticals Daily , Blackrock Inc , Dimensional Fund Advisors , Earnings History For Xenon Pharmaceuticals , Xenon Pharmaceuticals , Cantor Fitzgerald , Xenon Pharmaceuticals Inc , Institutional Investors Weigh In On Xenon Pharmaceuticals , Citigroup Inc , Jpmorgan Chase Co , Needham Company , Get Rating , Director Simon , Fund Advisors , Allianz Asset Management Gmbh , Asset Management Gmbh , Xenon Pharmaceuticals Daily , Nasdaq Xene ,